iCellate and Aptadel awarded Eurostars grant of 10 MSEK for novel cancer treatment and companion diagnostic
Stockholm 17 March 2022 – iCellate Medical, a Swedish genomic cancer diagnostics company and Spanish therapeutics company Aptadel have been awarded a grant of 10 MSEK from Eurostars for a first in-class RNA Aptamer-based targeted therapy for childhood cancer Ewing Sarcoma.For the second time in two years, iCellate has been awarded a substantial grant from Eurostars. As with the grant from 2020, for the Elevate project, iCellate will develop a new class of biomarker tests based on liquid biopsy to select patients for treatment with a new targeted cancer therapy. The Swedish government agency,